These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 35055244)

  • 1. Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa.
    Tang J; Cai L; Xu C; Sun S; Liu Y; Rosenecker J; Guan S
    Nanomaterials (Basel); 2022 Jan; 12(2):. PubMed ID: 35055244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal delivery of nanoparticle-based vaccines.
    Marasini N; Skwarczynski M; Toth I
    Ther Deliv; 2017 Jan; 8(3):151-167. PubMed ID: 28145824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal vaccine delivery: Current state and a pediatric perspective.
    Shakya AK; Chowdhury MYE; Tao W; Gill HS
    J Control Release; 2016 Oct; 240():394-413. PubMed ID: 26860287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nasal and pulmonary vaccine delivery using particulate carriers.
    Jia Y; Krishnan L; Omri A
    Expert Opin Drug Deliv; 2015 Jun; 12(6):993-1008. PubMed ID: 25952104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.
    Nagai M; Moriyama M; Ichinohe T
    mBio; 2021 Aug; 12(4):e0159821. PubMed ID: 34399617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bridging nanoplatform and vaccine delivery, a landscape of strategy to enhance nasal immunity.
    Teng Z; Meng LY; Yang JK; He Z; Chen XG; Liu Y
    J Control Release; 2022 Nov; 351():456-475. PubMed ID: 36174803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal formulations: promising strategy to deliver vaccines.
    Riese P; Sakthivel P; Trittel S; Guzmán CA
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1619-34. PubMed ID: 24962722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subunit-based mucosal vaccine delivery systems for pulmonary delivery - Are they feasible?
    Marasini N; Kaminskas LM
    Drug Dev Ind Pharm; 2019 Jun; 45(6):882-894. PubMed ID: 30767591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal vaccine design and delivery.
    Woodrow KA; Bennett KM; Lo DD
    Annu Rev Biomed Eng; 2012; 14():17-46. PubMed ID: 22524387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outer membrane vesicle-based intranasal vaccines.
    Van der Ley P; Schijns VE
    Curr Opin Immunol; 2023 Oct; 84():102376. PubMed ID: 37598549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances in the Noninvasive Delivery of mRNA.
    Qin M; Du G; Sun X
    Acc Chem Res; 2021 Dec; 54(23):4262-4271. PubMed ID: 34756014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nasal immunization with mannan-decorated mucoadhesive HPMCP microspheres containing ApxIIA toxin induces protective immunity against challenge infection with Actinobacillus pleuropneumoiae in mice.
    Li HS; Shin MK; Singh B; Maharjan S; Park TE; Kang SK; Yoo HS; Hong ZS; Cho CS; Choi YJ
    J Control Release; 2016 Jul; 233():114-25. PubMed ID: 27189136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary DNA vaccination: concepts, possibilities and perspectives.
    Bivas-Benita M; Ottenhoff TH; Junginger HE; Borchard G
    J Control Release; 2005 Sep; 107(1):1-29. PubMed ID: 16054263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Trends and Future Challenges of Nanovaccine Delivery
    Dewangan HK; Raghuvanshi A; Shah K
    Curr Drug Targets; 2023; 24(3):261-273. PubMed ID: 36475350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal Administration of Novel Chitosan Nanoparticle/DNA Complexes Induces Antibody Response to Hepatitis B Surface Antigen in Mice.
    Lebre F; Borchard G; Faneca H; Pedroso de Lima MC; Borges O
    Mol Pharm; 2016 Feb; 13(2):472-82. PubMed ID: 26651533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cell-targeting DNA-based nasal adjuvants for protective mucosal immunity to Streptococcus pneumoniae.
    Kataoka K; Fukuyama Y; Briles DE; Miyake T; Fujihashi K
    Microbiol Immunol; 2017 Jun; 61(6):195-205. PubMed ID: 28463465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines.
    Jin Z; Gao S; Cui X; Sun D; Zhao K
    Int J Pharm; 2019 Dec; 572():118731. PubMed ID: 31669213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic Toxoplasma gondii infection.
    Dimier-Poisson I; Carpentier R; N'Guyen TT; Dahmani F; Ducournau C; Betbeder D
    Biomaterials; 2015 May; 50():164-75. PubMed ID: 25736506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens.
    Dotiwala F; Upadhyay AK
    Vaccines (Basel); 2023 Oct; 11(10):. PubMed ID: 37896988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Nasal Vaccines and the Associated Challenges.
    Nian X; Zhang J; Huang S; Duan K; Li X; Yang X
    Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.